Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Brooklyn, New York, USA.
Microb Drug Resist. 2021 Dec;27(12):1726-1732. doi: 10.1089/mdr.2020.0602. Epub 2021 Jun 1.
Cystic fibrosis (CF) is associated with frequent pulmonary exacerbations and the need for novel antibiotics against antimicrobial resistance. Cefiderocol is a newly approved therapeutic option active against a variety of multidrug resistant (MDR) bacteria such as gram-negative species commonly encountered by CF patients. This review describes the potential role of cefiderocol against , , , and complex. Cefiderocol is a potential therapeutic option for MDR pathogens with minimum inhibitory concentrations (MICs) of ≤4 mg/L. Due to the lack of evidence in the CF population, cefiderocol may be utilized in patients in which alternative options are lacking due to MDR organisms or rapid pulmonary decline.
囊性纤维化（CF）常伴有肺部感染加重，需要新型抗生素来对抗抗菌药物耐药性。头孢地尔是一种新批准的治疗方案，对多种多药耐药（MDR）细菌具有活性，如 CF 患者常见的革兰氏阴性菌。本文综述了头孢地尔对铜绿假单胞菌、鲍曼不动杆菌、肠杆菌科和 复杂菌的潜在作用。头孢地尔是一种潜在的治疗选择，用于治疗最小抑菌浓度（MIC）≤4mg/L 的 MDR 病原体。由于在 CF 人群中缺乏证据，头孢地尔可用于因 MDR 病原体或肺部快速恶化而缺乏替代方案的患者。
